Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Development of Phage Activated Bacterial Cancer Therapeutics for Colorectal Cancer.

FY 2011-12

Summary
One of the main issues with current cancer therapy is side effects: too much damage to healthy tissue, either from chemotherapy or surgery. Bacterial cancer therapy is a new approach to solving this problem. Starting with certain bacteria that are known to naturally accumulate in tumors, these bacteria are then modified in several ways. They are stripped of the factors that cause disease in humans; and they are engineered to sense if they are in a tumor. The bacteria are also genetically programmed to produce a molecule that is toxic to cancer cells, but only when in a tumor. However, there are still at least two obstacles to this strategy: reliably programming the bacteria to only activate in a tumor, and the risk of administering live bacteria to cancer patients, even with their disease-causing factors removed. Recently it was discovered that colorectal cancer tumors, the second leading cause of cancer deaths, naturally contain a high concentration of a specific bacterium, Fusobacterium nucleatum. This has opened the door to using these pre-existing bacteria in the tumor as a factory for producing cancer killing molecules. One way of delivering the necessary genetic code is to use bacteriophages, which are viruses that are harmless to humans and only infect 'their' specific bacteria, whereupon they incorporate their DNA into the bacteria's genetic code. I plan to engineer a Fusobacterium nucleatum bacteriophage that contains genetic code for producing molecules that are toxic to cancer cells. If these studies are successful, they would lead to a therapy wherein these bacteriophages would be administered orally, infect the bacteria in the tumor, causing these bacteria to kill the cancer cells in the tumor. It is hoped that this would be a treatment for colorectal cancer that would be very effective, potentially avoiding both the need for surgical removal of the colon, and/or chemotherapy, thus improving the quality of life of patients with colorectal cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255327
Name
Woodsworth Daniel J
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Development of Phage Activated Bacterial Cancer Therapeutics for Colorectal Cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bacterial Cancer Therapy; Bacteriophages; Cancer Therapy; Colorectal Cancer; Genetic Engineering; Microbial Engineering; Microbiology; Synthetic Biology
Abstract
One of the main issues with current cancer therapy is side effects: too much damage to healthy tissue, either from chemotherapy or surgery. Bacterial cancer therapy is a new approach to solving this problem. Starting with certain bacteria that are known to naturally accumulate in tumors, these bacteria are then modified in several ways. They are stripped of the factors that cause disease in humans; and they are engineered to sense if they are in a tumor. The bacteria are also genetically programmed to produce a molecule that is toxic to cancer cells, but only when in a tumor. However, there are still at least two obstacles to this strategy: reliably programming the bacteria to only activate in a tumor, and the risk of administering live bacteria to cancer patients, even with their disease-causing factors removed. Recently it was discovered that colorectal cancer tumors, the second leading cause of cancer deaths, naturally contain a high concentration of a specific bacterium, Fusobacterium nucleatum. This has opened the door to using these pre-existing bacteria in the tumor as a factory for producing cancer killing molecules. One way of delivering the necessary genetic code is to use bacteriophages, which are viruses that are harmless to humans and only infect 'their' specific bacteria, whereupon they incorporate their DNA into the bacteria's genetic code. I plan to engineer a Fusobacterium nucleatum bacteriophage that contains genetic code for producing molecules that are toxic to cancer cells. If these studies are successful, they would lead to a therapy wherein these bacteriophages would be administered orally, infect the bacteria in the tumor, causing these bacteria to kill the cancer cells in the tumor. It is hoped that this would be a treatment for colorectal cancer that would be very effective, potentially avoiding both the need for surgical removal of the colon, and/or chemotherapy, thus improving the quality of life of patients with colorectal cancer.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Woodsworth, Daniel J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~